StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.94−0.05 (-2.27%)

Close on Nov 17, 2026Market cap $422.73MP/E –Yield –

CytomX Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

CytomX Therapeutics's price to sales ratio was 21.1× on Nov 11, 2026, against 4.4× a year earlier. Over the last 5 years it ranged from 0.4× to 33.3×, with a median of 2.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202621.1×+16.8
2025Dec 31, 20254.4×+3.7
2024Dec 31, 20240.7×−0.5
2023Dec 29, 20231.1×−1.2
2022Dec 30, 20222.4×−6.1
2021Dec 31, 20218.5×+4.1
2020Dec 31, 20204.3×−1.9
2019Dec 31, 20196.2×−2.8
2018Dec 31, 20189.0×−6.4
2017Dec 29, 201715.4×−21.8
2016Dec 30, 201637.2×+34.2
2015Dec 31, 20153.0×–

More CytomX Therapeutics figures

See a number that looks wrong?